股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF301 第 1 頁 共 10 頁 v 1.1.1 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 健培苗苗(保健)有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02161 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.01 | HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | ...

NOTIFICATION LETTER 通知信函 12 December 2025 Dear Non-registered Shareholder(s)(Note 1), JBM (Healthcare) Limited (the "Company") – Notice of publication of 2025/2026 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are available on the Company's website at www.jbmhealthcare.com.hk and the website of The Stock Exchange of Hong Kong Limited at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recomme ...

JBM (Healthcare) Limited 健倍 苗 苗 保健 有 限 公司 ( ) (Incorporated in the Cayman Islands with limited liability) （於開曼群島註冊成立的有限公司） (Stock Code 股份代號：2161) NOTIFICATION LETTER 通知信函 12 December 2025 Dear Registered Shareholder(s), JBM (Healthcare) Limited (the "Company") – Notice of publication of 2025/2026 Interim Report (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communication are now available on the Company's website at www.jbmhealthcare.com.hk and th ...

健倍苗苗（保健）有限公司 聚力前行 Focus Forward 2025/2026 中期報告 202 5/2026 INTERIM REPORT 中期報告 目錄 | 2 | | | --- | --- | | | 公司資料 | 於開曼群島註冊成立的有限公司 股份代號 : 2161 3 財務摘要 4 我們的願景及使命 5 公司簡介 6 管理層討論及分析 16 其他資料 22 致董事會的審閱報告 23 未經審核綜合損益及其他全面收益表 24 未經審核綜合財務狀況表 25 未經審核綜合權益變動表 26 未經審核簡明綜合現金流量表 27 未經審核中期財務報告附註 41 詞彙 公司資料 董事會 執行董事 岑廣業先生（主席） 嚴振亮先生 鄭香郡博士 黃一偉先生（行政總裁） （於二零二五年七月八日辭任） 非執行董事 楊國晉先生 徐宏喜博士 （於二零二五年十月二日獲委任） 獨立非執行董事 陳錦釗先生 陸庭龍先生 劉述理先生 審核委員會 陸庭龍先生（主席） 陳錦釗先生 劉述理先生 薪酬委員會 陸庭龍先生（主席） 嚴振亮先生 陳錦釗先生 劉述理先生 提名委員會 岑廣業先生（主席） 鄭香郡博士 （於二零二五年七月二十八日獲委任） ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 健培苗苗(保健)有限公司(於開曼群島註冊成立的有限公司) 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02161 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | HKD | | 0.01 HKD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 5,000,000,000 | HKD | | 0.01 HKD | | 50,000,000 | 本月 ...

Group 1 - The stock of Jianbei Miaomiao (02161.HK) increased by over 5%, specifically by 5.19%, reaching a price of 3.04 HKD [2] - The trading volume amounted to 1.5588 million HKD [2]

Group 1 - The company "健倍苗苗" announced a dividend of HKD 0.0975 per share, with an ex-dividend date of November 28, 2025, and a payment date of December 17, 2025 [1] - The 中证港股通央企红利指数 (CSI) consists of 50 high-dividend stocks from central enterprises, with a one-year dividend yield of 5.59% as of November 17, which is higher than the 10-year government bond yield of 3.77% [1] - The 恒生中国内地企业高股息率指数 (HSMCHYI) includes high-dividend stocks from mainland companies listed in Hong Kong, with a one-year dividend yield of 5.25% as of November 17, surpassing the 10-year government bond yield of 3.43% [1] Group 2 - The 港股央企红利ETF (513910) is the largest investment vehicle tracking the CSI index [1] - The 恒生红利ETF (159726) is the only ETF tracking the HSMCHYI index [1]

Core Viewpoint - The company Jianbei Miao Miao (02161) reported a strong performance in its interim results, leading to a significant increase in its stock price by over 5% [1] Financial Performance - The company reported revenue of approximately HKD 430 million for the six months ending September 30, 2025, representing a year-on-year increase of about 7.7% [1] - The profit attributable to equity holders was approximately HKD 115 million, reflecting a year-on-year increase of about 20.0% [1] - Earnings per share were reported at 14.12 HKD cents, with an interim dividend of 9.75 HKD cents per ordinary share [1] Business Segments - The growth in performance was primarily driven by strong sales from core brands, particularly in the branded pharmaceuticals segment with He Ji Gong and the traditional Chinese medicine segment with Bao Ji Wan [1] - The company's focus on brand management and effective market promotion execution contributed to the positive sales performance [1] - The traditional Chinese medicine formula granules business also showed stable performance, providing continuous contributions to the health business group [1]

Core Viewpoint - The company Jianbei Miaomiao (02161) reported a strong performance in its interim results, leading to a significant increase in its stock price by over 5% [1] Financial Performance - The company reported revenue of approximately HKD 430 million for the six months ending September 30, 2025, representing a year-on-year increase of about 7.7% [1] - The profit attributable to equity holders was approximately HKD 115 million, reflecting a year-on-year increase of about 20.0% [1] - Earnings per share were reported at 14.12 HKD cents, with an interim dividend of 9.75 HKD cents per ordinary share [1] Business Segments - The growth in performance was primarily driven by strong sales from core brands, particularly the branded pharmaceutical segment's He Jigong and the traditional Chinese medicine segment's Baoji Wan [1] - The company attributed its success to focused brand management and effective market promotion execution [1] - The traditional Chinese medicine formula granules business also showed stable performance, contributing consistently to the overall health business group [1]

Core Viewpoint - The company, Jianbei Miaomiao (02161), announced a mid-term dividend of HKD 0.0975 per share, to be distributed on December 17, 2025 [1] Company Summary - Jianbei Miaomiao will distribute a mid-term dividend of HKD 0.0975 per share [1]